- Trials with a EudraCT protocol (5)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
5 result(s) found for: Hepatic flexure.
Displaying page 1 of 1.
EudraCT Number: 2009-015077-12 | Sponsor Protocol Number: rrk3681 | Start Date*: 2009-11-23 |
Sponsor Name:University Hospital Birmingham NHS Foundation Trust | ||
Full Title: The use of corticosteroids (Budenofalk) as a chemopreventative agent in ulcerative colitis associated neoplasia | ||
Medical condition: chronic ulcerative colitis | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2018-003304-39 | Sponsor Protocol Number: 007 | Start Date*: 2019-01-23 | ||||||||||||||||
Sponsor Name:Morten Rasmussen | ||||||||||||||||||
Full Title: Efficacy of a novel 1l PEG plus ascorbate (Plenvu) bowel preparation vs. 2l PEG plus ascorbate (Moviprep), a randomized controlled multicenter trial | ||||||||||||||||||
Medical condition: Bowel preparation before colonoscopy | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-000347-60 | Sponsor Protocol Number: TTD-18-01 | Start Date*: 2018-08-08 | |||||||||||
Sponsor Name:Grupo de Tratamiento de los Tumores Digestivos (TTD) | |||||||||||||
Full Title: Phase III randomized sequential open-label study to evaluate the efficacy of FOLFOX + panitumumab followed by FOLFIRI + bevacizumab (Sequence 1) versus FOLFOX + bevacizumab followed by FOLFIRI + pa... | |||||||||||||
Medical condition: metastatic colorectal cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) PT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-000939-33 | Sponsor Protocol Number: MLN0002-3026 | Start Date*: 2015-11-11 | |||||||||||
Sponsor Name:Takeda Development Centre Europe, Ltd. | |||||||||||||
Full Title: A Randomized, Double-Blind, Double-Dummy, Multicenter, Active-Controlled Study to Evaluate the Efficacy and Safety of Vedolizumab IV Compared to Adalimumab SC in Subjects With Ulcerative Colitis | |||||||||||||
Medical condition: Ulcerative Colitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) SK (Completed) NL (Completed) BG (Completed) GB (Completed) DE (Completed) HU (Completed) BE (Completed) ES (Completed) LV (Completed) EE (Completed) LT (Completed) PL (Completed) DK (Completed) PT (Completed) HR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001776-15 | Sponsor Protocol Number: MS202202-0002 | Start Date*: 2020-11-16 | |||||||||||
Sponsor Name:Merck Healthcare KGaA | |||||||||||||
Full Title: A Phase II single-arm study to investigate tepotinib combined with cetuximab in RAS/BRAF wild-type left-sided metastatic colorectal cancer (mCRC) patients having acquired resistance to anti-EGFR... | |||||||||||||
Medical condition: left-sided metastatic colorectal cancer (mCRC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Prematurely Ended) CZ (Prematurely Ended) BE (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
